

EXPEDITING TIME TO TRIAL FOR COVID-19 PATIENT RESPIRATORY TREATMENT



Introduction

At the Meary Center for Cell and Gene Therapy in France, directed by Professor Jérôme Larghero, Dr. Guillaume Churlaud and his team are contributing to a treatment for COVID-19 patients now in a clinical trial [Sept. 2020]. Their cell production expertise was essential for the development of this cell therapy.

Working with several teams within Assistance Publique – Hôpitaux de Paris (AP-HP), they aim to treat intubated -ventilated patients with severe acute respiratory syndrome (SARS Cov2) caused by coronavirus.

The treatment consists of three intravenous administrations of mesenchymal stromal cells (MSCs), repeated every 48 hours. They hope that this treatment will alleviate the patients' respiratory symptoms and improve their medical state.

The NucleoCounter® NC-200™ provides a fast, reproducible, and repeatable method of cell counting between operators. In our hands, we found that it was easy to use and we only needed a short training session on the device before we could start using it.

The pros of this automated cell counter are definitely the robust and fast data acquisition and having 21 CFR Part 11-compliant software. It is well worth the upgrade from manual cell counting as it expedites our path to the clinic for this treatment.

Dr. Guillaume Churlaud, Meary Center for Cell and Gene Therapy

Challenges

“Since this clinical trial was set up so quickly, everything had to be done fast, including validation of the cell counting method for MSCs using the NucleoCounter® NC-200™”, says Dr. Guillaume Churlaud, when asked which challenges his team faced in this COVID-19 trial.

“Before, our cell counting and viability were determined by manual cell counting, using a counting chamber [hemacytometer] and trypan blue. The method was fast, but we saw variable data depending on the operator. We also used a flow cytometer, which was reproducible but a more time-consuming method.”

Learn more about the Meary Center at:
www.centremearly.aphp.fr



FAST-TRACK CLINICAL TRIALS WITH UNRIVALLED PRECISION AND EASE OF USE:

- Dedicated assay for MSCs
- Easily counts cells with debris and in aggregates
- Minimal variation between users and sites
- Standardizes cell counting process
- Expedites go-to-market time
- Regulatory bodies recognize our instruments
- Easy to incorporate into SOPs and validate
- 21 CFR Part 11-ready software



NucleoCounter® NC-200™